On November 30, 2022 LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) reported that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday, December 7, 2022 at 3:30 p.m. EST/12:30 p.m. PST (Press release, Lixte Biotechnology, DEC 2, 2022, View Source [SID1234624741]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
John S. Kovach, M.D., founder and CEO of LIXTE, will host the presentation. Dr. Kovach, with his team, will be answering questions at the conclusion.
To access the presentation, please use the following information
Planet MicroCap Showcase: VIRTUAL 2022
Date: Wednesday, December 7, 2022
Time: 3:30 p.m. EST/12:30 p.m. PST
Webcast: View Source
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers.
To view LIXTE Biotechnology Holdings’ presentation at the Planet MicroCap conference, register in advance at: View Sourcesignup" target="_blank" title="View Sourcesignup" rel="nofollow">View Source
The Planet MicroCap Showcase: VIRTUAL 2022 website is available at View Source
All company presentations as part of the conference will be available directly on the conference event platform on this link under the tab "Agenda" at: View Sourceagenda